KROS Q4 2025 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$385,000-87.3% YoY

Gross Profit

$00.0% margin

Operating Income

-$29M-7602.6% margin

Net Income

-$23M-6093.8% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-97.3%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$338M

Total Liabilities

$35M

Stockholders' Equity

$303M

Cash & Equivalents

$287M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$385,000	$3M	-87.3%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$29M	-$53M	+45.0%
Net Income	-$23M	-$46M	+49.0%

Revenue Segments

Service, Other

$385,000100%